America’s Blood Centers appreciates the opportunity to comment as part of this roundtable discussion. We also thank the FDA for convening industry, government, and blood community stakeholders on this issue, and for FDA’s ongoing work to harmonize
data standards and advance innovative product approvals that benefit patients and donors.
Posted in Letters and Comments